



GLOBAL UPDATE ON PAIN (V)

25th-28th October 2012

ORGANIZED BY:

Dept. of Anaesthesiology & Pain, Lilavati Hospital and Research Center and
Pain Management and Research Foundation-India

Under the Auspices of
Lilavati Hospital and Research Center, Mumbai India.

GLOBAL UPDATE ON PAIN (V)



Academic Co-sponsors:
Pan Arab Institute of Pain-Egypt
Dept of Anaesthesiology & Anatomy, Grant Medical College & J. J. Group of Hospitals, Mumbai.

Dear Colleagues,

We are basking in the glory of the grand success of the previous four Global Updates on Pain (2000, 2003, 2006 and 2009). Now Pain Management and Research Foundation and Dept. of Anaesthesiology & Pain of Lilavati Hospital and Research Center are organizing Global Update on Pain (V) to be held on 25th-28th October 2012.

Global Updates on Pain held till date were in true sense Global as these meetings had academic co-sponsors worldwide such as: UICC (Switzerland); Indian Society for Study of Pain; Royal Society of Medicine (RSM); Specialist in Pain International Network (SPIN-U.K.); Egyptian Pain Society; Mumbai Pain Management Group and Grant Medical College and JJ Group of Hospitals, Mumbai.

Pain Management and Research Foundation-India is a scientific body to promote the cause of Pain and its management. Its activities include organizing of Global Updates on Pain (every three year since 2000); international guest lectures, panel discussion and symposia. Pain Exhibition, Pain Management Awareness Program and T.V. talks are highlights of its activities.

PAN ARAB INSTITUTE OF PAIN (PAIP)

Th PAIP was founded in 2003 amongst Egypt, Saudi Arabia, Jordan, Iraq, Libia, Algeria and Lebanon. The first president of this institute was late Professor Omar Tawfik, Chairman of the Department of Anesthesiology and Pain Management at National Cancer Institute, Cairo University.

The PAIP is an institute aiming to gather most of the pain societies in the region of the Middle East. The aim is to connect pain practitioners in this region to cooperate scientifically in the field of pain management.

The new council is formed from eleven members representing all the countries mentioned above. The residence of the PAIP is in Cairo, Egypt.

THE VENUE

Lilavati Hospital and Research Centre, the premier multi speciality tertiary care hospital of India has been acknowledged globally as centre of medical excellence. The kind of confidence, trust it has developed on strong foundation of the state-of-the-art facilities, best medical and non-medical expertise, research, education and charitable endeavors; that today it serves patients from all walks of life-national and international. Lilavati Hospital has a continuous commitment to quality human care which truly reflects the essence of its motto "**More than Healthcare, Human Care**". It has an active Pain Management Clinic (PMC) and has post operative pain management program. The PMC offers variety of interventional pain treatment procedures for all types of chronic pain patients.

The conference will be at adjacent **Mumbai Educational Trust** auditorium.

This meeting will have Plenary sessions, Seminars, Symposia, Panel discussions and Poster presentations. There will be Hands on Cadaver Workshop as well as Live Demonstration Workshop.

"**Pain Exhibition**" and "**Pain Awareness Program**" for lay people will be additional highlights of the meeting.



Lilavati Hospital & Research Centre
More than Healthcare, Human care



SCIENTIFIC PROGRAM HIGHLIGHTS

Symposia

- Spinal Pain-(Discogenic, Nerve Root Compression, Facet jt.)
- Neuropathic Pain
- Bone Pain
- Diabetic Neuropathy
- Urogenital Pain
- Pain In ICU
- Orofacial Pain
- Podium & Poster Presentations
- Hands On Cadaver Workshop
- Cancer Pain
- Stump Pain
- Post Operative Pain
- Paediatric Pain
- Pain In Trauma
- Pain In AIDS
- Live Demonstration Workshop
- Interventional Pain Techniques

SOCIAL EVENTS

Entertaining social events are being planned for both delegates and accompanying persons.

The second announcement brochure will have details regarding scientific program, registration, accommodation, pre and post congress tour and other relevant information

ORGANIZING COMMITTEE

Patron

Dr. Subhash Jain (USA)

President
Sushila Shah

International President
Sanjay Bakshi (USA)

VICE PRESIDENTS

B. J. Damany

V. M. Divekar

Indula Panchal

Saroj Sanghavi

JOINT SECRETARIES

Anil Parakh

Smita Sharma

Kailash Kothari

TREASURER

Ketan Parikh

SCIENTIFIC COMMITTEE

Preeti Doshi (Chairman)

Jitendra Jain (Co-Chairman)

CADAVER WORKSHOP CO-ORDINATORS

B. Kondwilkar

S. D. Gangane

ORGANIZING CHAIRMAN

D. K. Baheti

ORGANIZING SECRETARIES

R. P. Gehdoo

Satish Kulkarni

SECRETARIAT

Marketing Dept., 3rd Floor, Lilavati Hospital & Research Centre,
A-791, Bandra Reclamation, Bandra (W), Mumbai, India-400 050
Email: globalpain2012@gmail.com • Web: www.painfoundationindia.com



With best compliments from

myoril™
back in action

In musculoskeletal spasm associated with

Low back pain Torticollis Sprains & Strains Injury



- Fast onset of action¹
- Free of sedative effects²
- Dosage compliance for patients (1 tab b.i.d.)

1. Myoril Core Brochure, data on file 2. Keleni Int. J Clin Pract. 2005 Jul;59(7):764-70

Myoril® 4 Plus

Composition: Each film coated tablet contains Thiocholicoside 4 / 8 mg and Ketoprofen IP 50 / 100mg. **Indications:** Treatment of painful muscular spasms in acute rheumatological and orthopedic conditions, including acute low back pain, degenerative vertebral disorders, periarthropathies, tendinopathies and traumatic injuries to muscles and tendons. **Dosage and method of administration:** For oral administration, 1 tablet of Myoril 8 Plus bid for 5 to 7 days. **Contraindications:** Hypersensitivity to any active or any of the excipients; history of hypersensitivity to ketoprofen, aspirin or other NSAIDs; pregnancy and lactation; severe heart failure; active or history of peptic ulcer/hemorrhage; history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy; severe hepatic / renal insufficiency. **Warnings:** Not recommended in children; reduce the dosage in case of diarrhoea. Not to be taken by patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Use minimum effective dose for shortest duration to minimize undesirable effects. Caution in patients receiving concomitant medications such as oral corticosteroids, anticoagulants, selective serotonin-reuptake inhibitors or anti-platelet agents such as aspirin. GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs. Elderly have increased frequency of adverse reactions to NSAIDs. Serious skin reactions, some of them fatal, have been reported very rarely in association with the use of NSAIDs. **Precautions:** Reduce dose in case of diarrhoea; may precipitate seizures in patients with epilepsy or those at risk of seizures. Give with care in case of history of gastrointestinal disease. Renal function to be carefully monitored at the start of treatment in patients with heart failure, cirrhosis and nephrosis, patients receiving diuretic therapy, patients with chronic renal impairment, particularly if elderly. Caution in patients with history of hypertension and/or mild to moderate congestive heart failure. Careful consideration in treating patients with existing uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, and/or cerebrovascular disease. May mask usual signs of infection such as fever. Transaminase levels to be evaluated in patients with abnormal liver function tests or with a history of liver disease, rare cases of jaundice and hepatitis have been reported with ketoprofen. Treatment to be discontinued in case of visual disturbances. May impair female fertility. **Pregnancy and lactation:** Contraindicated in pregnancy and lactation. **Undesirable effects:** Gastrointestinal effects; hypersensitivity reactions; skin reactions; peripheral and central nervous system; psychotic, vision, hearing disorders; renal and liver system; haematology and cardiovascular system. Headache, weight gain, oedema and taste perversion. For full prescribing information please write to Sanofi-Synthelabo (India) Ltd., Sir M. V. Road, Andheri, Mumbai 400093, Maharashtra, India. Tel: 022 28278000
Date: June 2008 Source: Ketoprofen CCDS Version V2, 11 January 2007 and Myoril Capsule PI Nov 2005

Sanofi-Synthelabo (India) Limited, 54/A, Sir Mathuradas Vasanji Road, Andheri (E), Mumbai 400 093. Tel: (91-22) 2827 8000. Fax: (91-22) 2837 0939

